Caseware UK (AP4) 2024.0.164 2024.0.164 2024-06-30 2024-06-30 4 true 2024-05-30 false false The company is dormant and has not traded during the period true 15750921 2024-05-29 15750921 2024-05-30 2024-06-30 15750921 2023-05-30 2024-05-29 15750921 2024-06-30 15750921 c:Director3 2024-05-30 2024-06-30 15750921 d:CurrentFinancialInstruments 2024-06-30 15750921 d:ShareCapital 2024-06-30 15750921 c:OrdinaryShareClass1 2024-05-30 2024-06-30 15750921 c:OrdinaryShareClass1 2024-06-30 15750921 c:EntityHasNeverTraded 2024-05-30 2024-06-30 15750921 c:FRS102 2024-05-30 2024-06-30 15750921 c:AuditExempt-NoAccountantsReport 2024-05-30 2024-06-30 15750921 c:FullAccounts 2024-05-30 2024-06-30 15750921 c:PrivateLimitedCompanyLtd 2024-05-30 2024-06-30 15750921 e:PoundSterling 2024-05-30 2024-06-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15750921 PROGNOSIS BIOTECH LTD UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD FROM 30 MAY 2024 TO 30 JUNE 2024
PROGNOSIS BIOTECH LTD
CONTENTS
| Page
Balance sheet | 1
Notes to the financial statements | 2 - 3
PROGNOSIS BIOTECH LTD REGISTERED NUMBER:15750921
BALANCE SHEET AS AT 30 JUNE 2024
|  | 2024
Note |  | £
Current assets |  |  |
Debtors: amounts falling due within one year |  | 250,000 |
|  | 250,000 |
Total assets less current liabilities |  |  | 250,000
Net assets |  |  | 250,000
Capital and reserves |  |  |
Called up share capital |  |  | 250,000
|  |  | 250,000
For the period ended 30 June 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006. Members have not required the company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 4 December 2025.
A Ntantasios
Director
The notes on pages 2 to 3 form part of these financial statements. 1
PROGNOSIS BIOTECH LTD
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2024
1. | General information
ProGnosis Biotech Ltd is a private company, limited by shares, registered in England and Wales, registration number 15750921. The registered office address is Elsley Court, 20-22 Great Titchfield Street, London, W1W 8BE. The company was incorporated on 30 May 2024. The company is dormant and has not traded during the period. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The company's functional and presentational currency is pound sterling. The following principal accounting polices have been applied.
| 2.2 | Debtors
Short-term debtors are measured at transaction price, less any impairment.
3. | Employees
| The average monthly number of employees, including directors, during the period was 4.
4. | Debtors
|  |  |  |  | 2024
|  |  |  |  | £
| Amounts owed by group undertakings | 250,000
5. | Share capital
|  |  |  |  | 2024
|  |  |  |  | £
|  | Allotted, called up and fully paid |
|  | 25,000 Ordinary shares of £10.00 each | 250,000
25,000 ordinary shares of £10 each were issued on incorporation at an aggregate nominal value of £250,000. 2
PROGNOSIS BIOTECH LTD
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2024
6. | Related party transactions
| No disclosure has been made of transactions with other wholly owned group companies in accordance with FRS 102 Section 1A paragraph 1AC.35.
3